Related Experiment Video

Updated: May 6, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K

PARP inhibitors: an interesting pathway also for non-small cell lung cancer?

Matteo Giaj Levra, Ken Andre Olaussen, Silvia Novello

  • 1Department of Oncology, University of Torino, Regione Gonzole 10, 10043 Orbassano (TO), Italy. silvia.novello@unito.it.

Current Pharmaceutical Design
|November 7, 2013
PubMed

Insights

This review explores Poly (ADP-ribose) polymerase (PARP) inhibitors for lung cancer treatment. Understanding DNA repair pathways is key to optimizing PARP inhibitors for non-small cell lung cancer (NSCLC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer treatment is advancing through molecular profiling of tumors.
  • DNA repair dysfunction, particularly involving Poly (ADP-ribose) polymerase (PARP), is implicated in lung cancer.
  • Existing literature on PARP in lung cancer as a biomarker and therapeutic target is limited.

Purpose of the Study:

  • To review current data on PARP's role in DNA repair pathways.
  • To summarize clinical data on PARP inhibitors in lung cancer.
  • To highlight the importance of understanding DNA damage response in NSCLC for PARP inhibitor development.

Main Methods:

  • Literature review of studies on PARP, DNA repair, and PARP inhibitors in lung cancer.
  • Analysis of data regarding synthetic lethality and sensitization to cytotoxic agents.
  • Examination of clinical trial outcomes for PARP inhibitors in NSCLC.

Main Results:

  • Pharmacological inhibition of PARP reveals synthetic lethality with proteins like BRCA1.
  • PARP inhibitors show potential in sensitizing tumors to conventional chemotherapy.
  • Data on PARP's clinical utility in lung cancer is still emerging.

Conclusions:

  • A comprehensive understanding of DNA damage response and its interplay with genetic stability is crucial.
  • Optimizing the development and application of PARP inhibitors in non-small cell lung cancer (NSCLC) requires further research.
  • Targeting DNA repair pathways represents a promising strategy for improving lung cancer therapy.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K